Payment overview · 2025
General Payments
$181,495.72
181 reported records · 15 companies
Healthcare provider profile · identity verified
Christopher Peter Lucci, MD
Allopathic & Osteopathic Physicians|Preventive Medicine|Public Health & General Preventive Medicine · ROCKPORT, TX · NPI 1447241955
Verified facts
What the public records show
CMS Open Payments records show Christopher Peter Lucci, MD received $181,495.72 in general payments during 2025 across 181 reported records.
Corcept Therapeutics accounted for 57.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 20 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Kerendia, Korlym, Ozempic, Recorlev, Rybelsus.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 116 claims for Kerendia by this doctor in 2024.
Corcept Therapeutics reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Korlym as an associated drug or biological on 56316 records involving 19205 distinct recipient NPIs. Public Medicare Part D data also shows 80 claims for Korlym by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 408 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 76 claims for Rybelsus by this doctor in 2024.
Xeris Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported RECORLEV as an associated drug or biological on 10044 records involving 3629 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Recorlev by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $103,778.87 | 57.2% | 85 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $76,946.50 | 42.4% | 66 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $198.68 | 0.1% | 8 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $97.82 | 0.1% | 4 | 2025 |
| Mannkind Corporation | Unresolved — no canonical attribution shown | $85.15 | 0.1% | 3 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $85.00 | 0.1% | 4 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $84.22 | 0.1% | 1 | 2025 |
| RECORDATI_RARE_DISEASES_INC. | Unresolved — no canonical attribution shown | $64.76 | 0.0% | 2 | 2025 |
| Tactile Systems Technology Inc | Unresolved — no canonical attribution shown | $31.27 | 0.0% | 1 | 2025 |
| BETA BIONICS, INC. | Unresolved — no canonical attribution shown | $27.42 | 0.0% | 2 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $21.87 | 0.0% | 1 | 2025 |
| TOLMAR, INC. | Unresolved — no canonical attribution shown | $21.50 | 0.0% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $19.32 | 0.0% | 1 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $18.51 | 0.0% | 1 | 2025 |
| Sequel Med Tech, LLC | Unresolved — no canonical attribution shown | $14.83 | 0.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $131,828.06 | 36 |
| Travel and Lodging | $31,679.81 | 59 |
| Consulting Fee | $8,820.00 | 3 |
| Honoraria | $4,913.00 | 2 |
| Food and Beverage | $4,212.35 | 80 |
| Education | $42.50 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $103,778.87 | 85 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $76,783.58 | 64 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $198.68 | 8 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $97.82 | 4 | 2025 |
Source payment records
|
|||||
| AFREZZA Normalized: afrezza |
Drug | Mannkind Corporation | $85.15 | 3 | 2025 |
Source payment records
|
|||||
| RECORLEV Normalized: recorlev |
Drug | Xeris Pharmaceuticals, Inc. | $85.00 | 4 | 2025 |
Source payment records
|
|||||
| STRENSIQ Normalized: strensiq |
Biological | Alexion Pharmaceuticals, Inc. | $84.22 | 1 | 2025 |
Source payment records
|
|||||
| ISTURISA Normalized: isturisa |
Drug | RECORDATI_RARE_DISEASES_INC. | $64.76 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $53.03 | 3 | 2025 |
Source payment records
|
|||||
| Flexitouch Plus Normalized: flexitouch plus |
Device | Tactile Systems Technology Inc | $31.27 | 1 | 2025 |
Source payment records
|
|||||
| Nimbl Normalized: nimbl |
Device | Tactile Systems Technology Inc | $31.27 | 1 | 2025 |
Source payment records
|
|||||
| iLet Bionic Pancreas Normalized: ilet bionic pancreas |
Device | BETA BIONICS, INC. | $27.42 | 2 | 2025 |
Source payment records
|
|||||
| iLet Insulin Infusion Kit Contact Detach Normalized: ilet insulin infusion kit contact detach |
Device | BETA BIONICS, INC. | $27.42 | 2 | 2025 |
Source payment records
|
|||||
| iLet Insulin Infusion Kit Inset Normalized: ilet insulin infusion kit inset |
Device | BETA BIONICS, INC. | $27.42 | 2 | 2025 |
Source payment records
|
|||||
| CRENESSITY Normalized: crenessity |
Drug | Neurocrine BioSciences, Inc. | $21.87 | 1 | 2025 |
Source payment records
|
|||||
| JATENZO Normalized: jatenzo |
Drug | TOLMAR, INC. | $21.50 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $19.32 | 1 | 2025 |
Source payment records
|
|||||
| UNITHROID Normalized: unithroid |
Drug | Amneal Pharmaceuticals LLC | $18.51 | 1 | 2025 |
Source payment records
|
|||||
| TWIIST Normalized: twiist |
Device | Sequel Med Tech, LLC | $14.83 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $12.66 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Kerendia kerendia |
2025 | Kerendia | 2024 | 116 | exact normalized | Medicare Part D |
| Korlym korlym |
2025 | Korlym | 2024 | 80 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 408 | exact normalized | Medicare Part D |
| RECORLEV recorlev |
2025 | Recorlev | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 76 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
116 | 15 |
| Corcept Therapeutics Exact reporting entity; no affiliate inference |
2025 | Korlym open payments reported associated product |
CMS Open Payments — General Payments 56316 supporting records · 19205 recipient NPIs · example record 1214133822 |
Korlym · 2024 Exact normalized brand match · 1 Part D row |
80 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
408 | 56 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
76 | 13 |
| Xeris Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | RECORLEV open payments reported associated product |
CMS Open Payments — General Payments 10044 supporting records · 3629 recipient NPIs · example record 1250146588 |
Recorlev · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Ozempic | Semaglutide | 408 | 56 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 309 | 81 |
| Celecoxib | Celecoxib | 164 | 34 |
| Atorvastatin Calcium | Atorvastatin Calcium | 158 | 42 |
| Levothyroxine Sodium | Levothyroxine Sodium | 157 | 40 |
| Mounjaro | Tirzepatide | 136 | 16 |
| Synthroid | Levothyroxine Sodium | 136 | 28 |
| Zolpidem Tartrate | Zolpidem Tartrate | 131 | 24 |
| Lisinopril | Lisinopril | 128 | 31 |
| Kerendia | Finerenone | 116 | 15 |
| Xarelto | Rivaroxaban | 108 | 19 |
| Farxiga | Dapagliflozin Propanediol | 102 | 20 |
| Tramadol Hcl | Tramadol Hcl | 88 | 28 |
| Amlodipine Besylate | Amlodipine Besylate | 81 | 18 |
| Gabapentin | Gabapentin | 80 | 12 |
| Korlym | Mifepristone | 80 | suppressed |
| Rybelsus | Semaglutide | 76 | 13 |
| Pioglitazone Hcl | Pioglitazone Hcl | 69 | 14 |
| Nebivolol Hcl | Nebivolol Hcl | 65 | 15 |
| Prednisone | Prednisone | 62 | 32 |
| Tamsulosin Hcl | Tamsulosin Hcl | 61 | 16 |
| Potassium Chloride | Potassium Chloride | 60 | 15 |
| Ezetimibe | Ezetimibe | 58 | 18 |
| Ondansetron Odt | Ondansetron | 58 | 24 |
| Furosemide | Furosemide | 57 | 19 |
| Metoprolol Succinate | Metoprolol Succinate | 57 | 15 |
| Vascepa | Icosapent Ethyl | 52 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 52 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 51 | 11 |
| Pantoprazole Sodium | Pantoprazole Sodium | 50 | 11 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 42 | 12 |
| Repatha Sureclick | Evolocumab | 40 | suppressed |
| Valsartan | Valsartan | 40 | 11 |
| Invokana | Canagliflozin | 39 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 38 | 27 |
| Jardiance | Empagliflozin | 37 | suppressed |
| Metformin Hcl | Metformin Hcl | 37 | 11 |
| Carvedilol | Carvedilol | 36 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 36 | suppressed |
| Nexlizet | Bempedoic Acid/Ezetimibe | 35 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 34 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 34 | suppressed |
| Azithromycin | Azithromycin | 33 | 25 |
| Losartan Potassium | Losartan Potassium | 31 | 11 |
| Omeprazole | Omeprazole | 30 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 30 | suppressed |
| Edarbyclor | Azilsartan Med/Chlorthalidone | 26 | suppressed |
| Eszopiclone | Eszopiclone | 26 | suppressed |
| Finasteride | Finasteride | 26 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 25 | suppressed |
| Myrbetriq | Mirabegron | 25 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 24 | suppressed |
| Allopurinol | Allopurinol | 24 | suppressed |
| Fluconazole | Fluconazole | 24 | suppressed |
| Entresto | Sacubitril/Valsartan | 23 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 23 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 23 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 23 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 23 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 23 | suppressed |
| Meloxicam | Meloxicam | 22 | suppressed |
| Eplerenone | Eplerenone | 21 | suppressed |
| Recorlev | Levoketoconazole | 21 | suppressed |
| Eliquis | Apixaban | 20 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 19 | suppressed |
| Ramipril | Ramipril | 19 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 19 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 18 | 12 |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 18 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 17 | suppressed |
| Febuxostat | Febuxostat | 17 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 17 | suppressed |
| Xyosted | Testosterone Enanthate | 17 | suppressed |
| Lorazepam | Lorazepam | 16 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 16 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 16 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 15 | suppressed |
| Januvia | Sitagliptin Phosphate | 15 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 15 | 13 |
| Tresiba Flextouch U-200 | Insulin Degludec | 15 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 15 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 14 | suppressed |
| Klor-Con M20 | Potassium Chloride | 14 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 14 | suppressed |
| Belsomra | Suvorexant | 13 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 13 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 13 | suppressed |
| Levofloxacin | Levofloxacin | 13 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 13 | suppressed |
| Livalo | Pitavastatin Calcium | 13 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 13 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 12 | suppressed |
| Bupropion Xl | Bupropion Hcl | 12 | suppressed |
| Forteo | Teriparatide | 12 | suppressed |
| Ketoconazole | Ketoconazole | 12 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Prolia | Denosumab | 12 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 12 | suppressed |
| Chlorthalidone | Chlorthalidone | 11 | suppressed |
| Colchicine | Colchicine | 11 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 11 | suppressed |
| Euthyrox | Levothyroxine Sodium | 11 | suppressed |
| Famotidine | Famotidine | 11 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 11 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 11 | suppressed |
| Invokamet Xr | Canagliflozin/Metformin Hcl | 11 | suppressed |
| Nifedipine Er | Nifedipine | 11 | suppressed |
| Trijardy Xr | Empaglifloz/Linaglip/Metformin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $181,495.72 · 181 records | Corcept Therapeutics | AFREZZA, CRENESSITY, Flexitouch Plus, GEMTESA, ISTURISA, JATENZO, Kerendia, Korlym, LEQVIO, Nimbl, Ozempic, RECORLEV, Rybelsus, STRENSIQ, TWIIST, UNITHROID, Wegovy, iLet Bionic Pancreas, iLet Insulin Infusion Kit Contact Detach, iLet Insulin Infusion Kit Inset | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Kerendia play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Bayer Healthcare Pharmaceuticals Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error